Abstract
The inhibition of α-glucosidase and α-amylase, enzymes involved in the digestion of carbohydrates, can significantly reduce the post-prandial increase of blood glucose and therefore can be an important strategy in the management of blood glucose level in type 2 diabetic and borderline patients. Currently, there is renewed interest in plant-based medicines and functional foods modulating physiological effects in the prevention and cure of diabetes and obesity. The plant kingdom is a wide field to search for natural effective oral hypoglycaemic agents that have slight or no side effects. More than ca. 1200 plant species have been recorded to be used empirically worldwide for their alleged hypoglycaemic activity. Therefore, natural α-glucosidase and α-amylase inhibitors from plant sources offer an attractive strategy for the control of hyperglycaemia. This article reviews recent data on plant extracts and isolated natural compounds that are being tested for their hypoglycaemic activity, highlights ongoing research and considers the future perspectives.
Keywords: Diabetes, Post-prandial Hyperglycaemia, α-Glucosidase, α-Amylase, Extract, Natural compounds
Mini-Reviews in Medicinal Chemistry
Title: Natural Products as α-Amylase and α-Glucosidase Inhibitors and their Hypoglycaemic Potential in the Treatment of Diabetes: An Update
Volume: 10 Issue: 4
Author(s): R. Tundis, M.R. Loizzo and F. Menichini
Affiliation:
Keywords: Diabetes, Post-prandial Hyperglycaemia, α-Glucosidase, α-Amylase, Extract, Natural compounds
Abstract: The inhibition of α-glucosidase and α-amylase, enzymes involved in the digestion of carbohydrates, can significantly reduce the post-prandial increase of blood glucose and therefore can be an important strategy in the management of blood glucose level in type 2 diabetic and borderline patients. Currently, there is renewed interest in plant-based medicines and functional foods modulating physiological effects in the prevention and cure of diabetes and obesity. The plant kingdom is a wide field to search for natural effective oral hypoglycaemic agents that have slight or no side effects. More than ca. 1200 plant species have been recorded to be used empirically worldwide for their alleged hypoglycaemic activity. Therefore, natural α-glucosidase and α-amylase inhibitors from plant sources offer an attractive strategy for the control of hyperglycaemia. This article reviews recent data on plant extracts and isolated natural compounds that are being tested for their hypoglycaemic activity, highlights ongoing research and considers the future perspectives.
Export Options
About this article
Cite this article as:
Tundis R., Loizzo M.R. and Menichini F., Natural Products as α-Amylase and α-Glucosidase Inhibitors and their Hypoglycaemic Potential in the Treatment of Diabetes: An Update, Mini-Reviews in Medicinal Chemistry 2010; 10 (4) . https://dx.doi.org/10.2174/138955710791331007
DOI https://dx.doi.org/10.2174/138955710791331007 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial (Thematic Issue: Current Therapeutic Options in Cardiomyopathies)
Current Pharmaceutical Design Association of Arterial Hypertension with Hepatobiliary Pathology: The Occurrence of Comorbidity and Features of Metabolic Processes
Current Hypertension Reviews Defining Statistical Race and Phenotypic Race and Their Implications for Health Disparities
Current Pharmacogenomics and Personalized Medicine Neuropeptides as Therapeutic Targets to Combat Stress-Associated Behavioral and Neuroendocrinological Effects
CNS & Neurological Disorders - Drug Targets Cell Immunity in Coronary Artery Disease (CAD)
Current Immunology Reviews (Discontinued) The Neuropharmacology of (-)-Stepholidine and its Potential Applications
Current Neuropharmacology Meet Our Editorial Board Member
Current Hypertension Reviews Vascular effects of flavonoids
Current Medicinal Chemistry Genetics of Atrial Fibrilation: In Search of Novel Therapeutic Targets
Cardiovascular & Hematological Disorders-Drug Targets Clinical Consequences and Novel Therapy of Hyperphosphatemia: Lanthanum Carbonate for Dialysis Patients
Recent Patents on Cardiovascular Drug Discovery Meet Our Editorial Board Member
Current Bioactive Compounds Heteromerization as a Mechanism Modulating the Affinity of the ACE2 Receptor to the Receptor Binding Domain of SARS-CoV-2 Spike Protein
Current Proteomics Can Marine Omega 3 Fatty Acids Prevent and/or Treat Metabolic Syndrome?
Current Nutrition & Food Science Cellular Balance, Genes,and the Huang Ti Nei Ching Su Wen
Current Neurovascular Research High Fat Diet-Induced Obesity Stimulate Depressive Behavior in Rats
Current Psychopharmacology Editorial [Hot Topic: Drugs Targeted to Improve Endothelial Function: Clinical Correlates Between Sexual and Internal Medicine (Executive Editor: Antonio Aversa)]
Current Pharmaceutical Design Poor Nutrition with Aging: an “Oxidatively Stressing” Condition
Current Nutrition & Food Science The Role of ROS and RNS in Regulating Life and Death of Blood Monocytes
Current Pharmaceutical Design Adult Changes in Thought Study: Dementia is an Individually Varying Convergent Syndrome with Prevalent Clinically Silent Diseases that may be Modified by Some Commonly Used Therapeutics
Current Alzheimer Research Functional Cardiovascular Effects of Angiotensin Peptides: Focus on Atherosclerosis and Hypertension
Current Hypertension Reviews